Publication Cover
Immunological Investigations
A Journal of Molecular and Cellular Immunology
Volume 30, 2001 - Issue 3
79
Views
7
CrossRef citations to date
0
Altmetric
Original

EFFECTS OF DEXAMETHASONE ON THE EXPRESSION OF FAS MOLECULES AND APOPTOSIS OF LYMPHOCYTES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

, , &
Pages 231-243 | Published online: 07 Jul 2009

REFERENCES

  • Klinman D. M., Steinberg A. D. Systemic Autoimmune Disease Arises from Polyclonal B Cell Activation. J. Exp. Med. 1987; 165(6)1755–1760
  • Bijl M., van Lopik T., Limburg P. C., Spronk P. E., Jaegers S. M., Aarden L. A., Smeenk R. J., Kallenberg G. G. Do Elevated Levels of Serum-soluble Fas Contribute to the Persistence of Activated Lymphocytes in Systemic Lupus Erythematosus?. J. Autoimmun. 1998; 11(5)457–463
  • Salmon M., Gordon C. The Role of Apoptosis in Systemic Lupus Erythematosus. Rheumatology (Oxford) 1999; 38(12)1177–1183
  • Rosen A., Casciola-Rosen L. Autoantigens as Substrates for Apoptotic Proteases: Implications for the Pathogenesis of Systemic Autoimmune Disease. Cell Death differ. 1999; 6(1)6–12
  • Cohen P. L., Eisenberg R. A. Lpr and gld: Single Gene Models of Systemic Autoimmunity and Lymphoproliferative Disease. Annu. Rev. Immunol. 1991; 9: 243–269
  • McDonnell J. J., Deane N., Platt F. M., Nunez G., Jaeger U., McKearn J. P., Korsmeyer S. J. bcl-2 Immunoglobulin Transgenic Mice Demonstrate Extended B Cell Survival and Follicular Lymphoproliferation. Cell 1989; 57(1)79–88
  • Ohsako S., Hara M., Harigai M., Fukasawa C., Kashiwazaki S. Expression and Function of Fas Antigen and bcl-2 in Human Systemic Lupus Erythematosus Lymphocytes. Clin. Immunol. Immunopathol. 1994; 73(1)109–114
  • Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S. The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas can Mediate Apoptosis. Cell 1991; 66(2)233–243
  • Cheng J., Zhou T., Liu C., Shapiro J. P., Brauer M. J., Kiefer M. C., Barr P. J., Mountz J. D. Protection from Fas-mediated Apoptosis by a Soluble Form of the Fas Molecule. Science 1994; 263(5154)1759–1762
  • Mysler E., Bini P., Drappa J., Ramos P., Friedman S. M., Krammer P. H., Elkon K. B. The Apoptosis-1/Fas Protein in Human Systemic Lupus Erythematosus. J. Clin. Invest. 1994; 93(3)1029–1034
  • Lorenz H., Grunke M., Hieronymus T., Herrmann M., Kuhnel A., Manger B., Kalden J. R. In vitro Apoptosis and Expression of Apoptosis-related Molecules in Lymphocytes from Patients with Wystemic Lupus Erythematosus and Other Autoimmune Diseases. Arthritis Rheum 1997; 40(2)306–317
  • Emlen W., Niebur J., Kadera R. Accelerated In vitro Apoptosis of Lymphocytes from Patients with Systemic Lupus Erythematosus. J. Immunol. 1994; 152(7)3685–3692
  • Papo T., Parizot C., Ortova M., Piette J. C., Frances C., Debre P., Godeau P., Gorochov G. Apoptosis and Expression of Soluble Fas mRNA in Systemic Lupus Erythematosus. Lupus 1998; 7(7)455–461
  • Tuosto L., Cundari E., Montani M. S., Piccolella E. Analysis of Susceptibility of Mature Human T Lymphocytes to Dexamethasone-induced Apoptosis. Eur. J. Immunol. 1994; 24(5)1061–1065
  • Brunetti M., Martelli N., Colasante A., Piantelli M., Musiani P., Aiello F. B. Spontaneous and Glucocorticoid-induced Apoptosis in Human Mature T Lymphocytes. Blood 1995; 86(11)4199–4205
  • Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthritis Rheum 1982; 25(11)1271–1277
  • Bombardier C., Gladman D. D., Urowitz M. B., Caron D., Chang C. H. The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: A Disease Activity Index for Lupus Patients. Arthritis Rheum 1992; 35(6)630–640
  • Amercian Thoracic Society. Guidelines for the Evaluation of Impairment/Di-Disability in Patients with Asthma. Am. Rev. Respir. Dis. 1993; 147: 1056–1061
  • Krammer P. H., Dhein J., Walczak H., Behrmann I., Mariani S., Matiba B., Fath M., Daniel P. T., Knipping E., Westendorp M. O. The Role of APO-1-mediated Apoptosis in the Immune System. Immunological Rev. 1994; 142: 175–191
  • Ju S. T., Panka D. J., Cui H., Ettinger R., el-Khatib M., Sherr D. H., Stanger B. Z., Marshak-Rothstein A. Fas (CD95)/FasL Interactions Required for Programmed Cell Death After T-cell Activation. Nature 1995; 373(6513)444–448
  • Nozawa K., Kayagaki N., Tokano Y., Yagita H., Okumura K., Hashimoto H. Soluble Fas (APO-1, CD95) and Soluble Fas Ligand in Rheumatic Diseases. Arthritis Rheum 1997; 40(6)1126–1129
  • Amasaki Y., Kobayashi S., Takeda T., Ogura N., Jodo S., Nakabayashi T., Tsutsumi A., Fujisaku A., Koike T. Up-regulated Expression of Fas Antigen (CD95) by Peripheral Naive and Memory T Cell Subsets in Patients with Systemic Lupus Erythematosus (SLE): A Possible Mechanism for Lymphopenia. Clin. Exp. Immunol. 1995; 99(2)245–250
  • Rose L. M., Latchman D. S., Isenberg D. A. Apoptosis in Peripheral Lymphocytes in Systemic Lupus Erythematosus: A Review. Br. J. Rheumatol. 1997; 36(2)158–163
  • Yoshino T., Kondo E., Cao L., Takahashi K., Hayashi K., Nomura S., Akagi T. Inverse Expression of bcl-2 Protein and Fas Antigen in Lymphoblasts in Peripheral Lymph Nodes and Activated Peripheral Blood T and B Lymphocytes. Blood 1994; 83(7)1856–1861
  • Sato T., Irie S., Kitada S., Reed J. C. FAP-1: A Protein Tyrosine Phosphatase that Associates with Fas. Science 1995; 268(5209)411–415
  • Giolstein P. Controlling Cell Death. Science 1997; 275(5303)1081–1082
  • Owen-Schaub L. B., Yonehara S., Crump W. L., Grimm E. A. DNA Fragmentation and Cell Death is Selectively Triggered in Activated Human Lymphocytes by Fas Antigen Engagement. Cell Immunol. 1992; 140(1)197–205
  • Nishioka Y., Lipsky P. E. The Role of CD40-CD40 Ligand Interaction in Human T cell-B Cell Collaboration. J. Immunol. 1994; 153(3)1027–1036
  • Aringer M., Wintersberger W., Steiner C. W., Kiener H., Presterl E., Jaeger U., Smolen J. S., Graninger W. B. High Levels of bcl-2 Protein in Circulating T Lymphocytes, but not B Lymphocytes, of Patients with Systemic Lupus Erythematosus. Arthritis Rheum 1994; 37(10)1423–1430

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.